3-Methyl-2-morpholin-4-yl-butylamine | 923176-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 3-Methyl-2-morpholin-4-yl-butylamine
• 英文别名: 3-methyl-2-morpholin-4-ylbutan-1-amine
• CAS: 923176-80-1
• 化学式: C₉H₂₀N₂O
• mdl: MFCD08444596
• 分子量: 172.27
• InChiKey: KUZCEYDTUIJKLG-UHFFFAOYSA-N

物化性质

• 沸点：
  246.4±20.0 °C(Predicted)
• 密度：
  0.969±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

文献信息

• Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
  申请人：NOVARTIS AG

  公开号：US20200383960A1

  公开（公告）日：2020-12-10

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了吡啶和吡嗪衍生物，可以恢复或增强突变型和/或野生型CFTR的功能，用于治疗支气管扩张、囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、口干症和角膜结膜炎，或便秘（肠易激综合征、炎症性肠病、阿片类药物诱导）。还包括含有这些衍生物的药物组合物。
• Pyridine and Pyrazine Derivative for the Treatment of CF
  申请人：BAETTIG Urs

  公开号：US20120277232A1

  公开（公告）日：2012-11-01

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了吡啶和吡嗪衍生物，用于恢复或增强突变和/或野生型CFTR的功能，以治疗囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、口干症和角膜结膜炎，或便秘（IBS，IBD，阿片类药物引起）。还包括含有这些衍生物的制药组合物。
• Pyridine and Pyrazine derivative for the Treatment of CF
  申请人：BAETTIG Urs

  公开号：US20150045364A1

  公开（公告）日：2015-02-12

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了吡啶和吡嗪衍生物，能够恢复或增强突变型和/或野生型CFTR的功能，以治疗囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、口干症和角膜结膜炎，或便秘（IBS、IBD、阿片类药物引起的）。还包括含有这些衍生物的药物组合物。
• Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease
  申请人：Novartis AG

  公开号：EP2845593A1

  公开（公告）日：2015-03-11

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat chronic obstructive pulmonary disease. Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了可恢复或增强突变型和/或野生型 CFTR 功能的吡啶和吡嗪衍生物，用于治疗慢性阻塞性肺病。本发明还包括包含此类衍生物的药物组合物。
• Pyridine and pyrazine derivative for the treatment of CF
  申请人：Novartis AG

  公开号：US10117858B2

  公开（公告）日：2018-11-06

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了吡啶和吡嗪衍生物，这些衍生物可恢复或增强突变型和/或野生型 CFTR 的功能，用于治疗囊性纤维化、原发性睫状肌运动障碍、慢性支气管炎、慢性阻塞性肺病、哮喘、呼吸道感染、肺癌、口角炎和角结膜炎或便秘（肠易激综合征、肠道综合征、阿片类药物诱发）。还包括由此类衍生物组成的药物组合物。